Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

Summary Background Biologically targeted therapies have been postulated as a viable strategy to improve outcomes for women with ovarian cancer. We assessed the safety, tolerance, pharmacokinetics, relevant circulating and image-derived biomarkers, and clinical activity of combination aflibercept and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2011-11, Vol.12 (12), p.1109-1117
Hauptverfasser:	Coleman, Robert L, Prof, Duska, Linda R, MD, Ramirez, Pedro T, Prof, Heymach, John V, MD, Kamat, Aparna A, MD, Modesitt, Susan C, MD, Schmeler, Kathleen M, MD, Iyer, Revathy B, Prof, Garcia, Michael E, RN, Miller, Debbie L, RN, Jackson, Edward F, Prof, Ng, Chaan S, Prof, Kundra, Vikas, MD, Jaffe, Robert, Prof, Sood, Anil K, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Angiogenesis Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Cancer therapies Cardiovascular disease Chemotherapy Drug dosages Fallopian Tube Neoplasms - drug therapy Fallopian Tube Neoplasms - pathology Fallopian tubes Female Growth factors Hematology, Oncology and Palliative Medicine Humans Hypertension Male Middle Aged Neoplasm Recurrence, Local Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Patients Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - pathology Pharmacokinetics Radiation Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins - administration & dosage Skin cancer Taxoids - administration & dosage Time Factors Treatment Outcome Tumors United States Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!